Say goodbye to heel pain! In this video, we break down the four best techniques for relieving plantar fasciitis using simple ...

Keenova Therapeutics plc, a leading US-focused branded therapeutics company, announced positive results from its phase 3 clinical trial of Xiaflex (collagenase clostridium histolyticum) for the ...

NBC Selected independently determines what we cover and recommend. When you click on or buy through our links, we earn a commission. Learn more. Mili Godio Updates Editor If you’re struggling with ...

Keenova Therapeutics is hoping to step into a new market with Xiaflex (collagenase clostridium histolyticum), after the drug netted a Phase III win in rare foot disease, plantar fibromatosis. To put ...

Treatment with CCH led to a clinically meaningful and statistically significant reduction in daily foot pain at week 12 compared with placebo. Topline data were announced from a phase 3 trial ...

Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium ...

The pivotal trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in pain versus placebo, as measured by the Average Daily Pain Intensity on ...

Keenova Therapeutics achieved statistically significant primary and secondary endpoints in its Phase 3 trial of XIAFLEX. The pivotal study demonstrated meaningful foot pain reduction and functional ...